Sysmex Suisse
Menu

Identifying poor antiplatelet drug response and adverse cardiovascular events risks early on

The evaluation of the effectiveness of antiplatelet medication and forecast of future cardiovascular complications are very important for many patients. The immature platelets are more reactive compared to mature platelets and have a higher prothrombotic potential. IPF# can be associated with poor antiplatelet drug response due to residual platelet reactivity and has been shown to have additional value compared to traditional platelet function tests. In this white paper the related scientific publications are explained.
File type:
pdf
File size:
318 KB
Release:
31-01-24
Copyright © Sysmex Europe SE. All rights reserved.